Integrated use of 90 Y-labeled microspheres and immune checkpoint inhibitors in hepatic tumors: current status and future directions.

Y-microspheres did not help sensitize microsatellite-stable CRCLM to immunotherapy. Particular caution should be paid in UMLM patients undergoing combination therapy with ipilimumab plus nivolumab. In this regard, the potential usefulness of provisional dosimetry to estimate the radiation burden delivered to the normal hepatic parenchyma, has still to be fully addressed.